Avalo Therapuetics (AVTX) Appoints Rita Jain to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- S&P 500, Nasdaq slip as Iran tensions test markets in high-stakes week
- Oil falls ahead of US announcement of new sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- S&P 500, Nasdaq slip as Iran tensions test markets in high-stakes week
- RUM Group signs $13.7 billion GPU services deal, issues warrants
- XPeng Inc. (XPEV) Misses Q2 EPS by 100c ; Provides Outlook
- Hungarian Gripen jet crashes, no injuries reported, PM Magyar says
Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors
June 18, 2025 7:00 AM EDTWAYNE, Pa., June 18, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced the appointment of Rita Jain, M.D. to its Board of Directors.
We are pleased to welcome Dr. Jain to Avalos Board of Directors, said Michael Heffernan, Chairman of the Board. Ritas extensive experience spanning clinical development, regulatory strategy, and executive leadership at multiple development-stage biopharma companies will be invaluable as we continue to advance AVTX-009, a high affinity anti-IL-1 monoclonal antibody... More
